vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and DMC Global Inc. (BOOM). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $143.5M, roughly 1.7× DMC Global Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -7.8%, a 18.9% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -5.8%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $9.6M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -7.3%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
DMC Mining Services is a mining services contractor founded in 1980 operating in Canada, the United States, Chile, and Mongolia
ANIP vs BOOM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $143.5M |
| Net Profit | $27.5M | $-11.2M |
| Gross Margin | — | 17.1% |
| Operating Margin | 14.1% | -7.8% |
| Net Margin | 11.1% | -7.8% |
| Revenue YoY | 29.6% | -5.8% |
| Net Profit YoY | 367.5% | -3871.6% |
| EPS (diluted) | $1.14 | $-0.60 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $143.5M | ||
| Q3 25 | $227.8M | $151.5M | ||
| Q2 25 | $211.4M | $155.5M | ||
| Q1 25 | $197.1M | $159.3M | ||
| Q4 24 | $190.6M | $152.4M | ||
| Q3 24 | $148.3M | $152.4M | ||
| Q2 24 | $138.0M | $171.2M | ||
| Q1 24 | $137.4M | $166.9M |
| Q4 25 | $27.5M | $-11.2M | ||
| Q3 25 | $26.6M | $-3.1M | ||
| Q2 25 | $8.5M | $116.0K | ||
| Q1 25 | $15.7M | $677.0K | ||
| Q4 24 | $-10.3M | $296.0K | ||
| Q3 24 | $-24.2M | $-101.3M | ||
| Q2 24 | $-2.3M | $4.0M | ||
| Q1 24 | $18.2M | $2.6M |
| Q4 25 | — | 17.1% | ||
| Q3 25 | — | 21.7% | ||
| Q2 25 | — | 23.6% | ||
| Q1 25 | — | 25.9% | ||
| Q4 24 | — | 20.8% | ||
| Q3 24 | — | 19.8% | ||
| Q2 24 | — | 27.1% | ||
| Q1 24 | — | 25.4% |
| Q4 25 | 14.1% | -7.8% | ||
| Q3 25 | 15.9% | 0.4% | ||
| Q2 25 | 6.6% | 2.5% | ||
| Q1 25 | 13.3% | 4.1% | ||
| Q4 24 | -2.3% | -0.5% | ||
| Q3 24 | -13.8% | -97.7% | ||
| Q2 24 | 3.7% | 6.8% | ||
| Q1 24 | 14.8% | 4.0% |
| Q4 25 | 11.1% | -7.8% | ||
| Q3 25 | 11.7% | -2.0% | ||
| Q2 25 | 4.0% | 0.1% | ||
| Q1 25 | 8.0% | 0.4% | ||
| Q4 24 | -5.4% | 0.2% | ||
| Q3 24 | -16.3% | -66.5% | ||
| Q2 24 | -1.7% | 2.3% | ||
| Q1 24 | 13.2% | 1.5% |
| Q4 25 | $1.14 | $-0.60 | ||
| Q3 25 | $1.13 | $-0.10 | ||
| Q2 25 | $0.36 | $-0.24 | ||
| Q1 25 | $0.69 | $0.04 | ||
| Q4 24 | $-0.45 | $-0.18 | ||
| Q3 24 | $-1.27 | $-8.27 | ||
| Q2 24 | $-0.14 | $0.24 | ||
| Q1 24 | $0.82 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $31.9M |
| Total DebtLower is stronger | — | $50.6M |
| Stockholders' EquityBook value | $540.7M | $242.1M |
| Total Assets | $1.4B | $635.8M |
| Debt / EquityLower = less leverage | — | 0.21× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $31.9M | ||
| Q3 25 | $262.6M | $26.4M | ||
| Q2 25 | $217.8M | $12.4M | ||
| Q1 25 | $149.8M | $14.7M | ||
| Q4 24 | $144.9M | $14.3M | ||
| Q3 24 | $145.0M | $14.5M | ||
| Q2 24 | $240.1M | $14.6M | ||
| Q1 24 | $228.6M | $20.4M |
| Q4 25 | — | $50.6M | ||
| Q3 25 | — | $56.5M | ||
| Q2 25 | — | $58.7M | ||
| Q1 25 | — | $72.4M | ||
| Q4 24 | — | $70.8M | ||
| Q3 24 | — | $74.2M | ||
| Q2 24 | — | $84.1M | ||
| Q1 24 | — | $88.0M |
| Q4 25 | $540.7M | $242.1M | ||
| Q3 25 | $505.8M | $253.0M | ||
| Q2 25 | $436.8M | $253.9M | ||
| Q1 25 | $418.6M | $253.9M | ||
| Q4 24 | $403.7M | $251.0M | ||
| Q3 24 | $405.9M | $256.5M | ||
| Q2 24 | $455.8M | $416.0M | ||
| Q1 24 | $452.0M | $409.9M |
| Q4 25 | $1.4B | $635.8M | ||
| Q3 25 | $1.4B | $644.1M | ||
| Q2 25 | $1.3B | $645.0M | ||
| Q1 25 | $1.3B | $670.6M | ||
| Q4 24 | $1.3B | $671.3M | ||
| Q3 24 | $1.3B | $702.0M | ||
| Q2 24 | $920.8M | $869.5M | ||
| Q1 24 | $914.5M | $860.0M |
| Q4 25 | — | 0.21× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | 0.29× | ||
| Q2 24 | — | 0.20× | ||
| Q1 24 | — | 0.21× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $15.2M |
| Free Cash FlowOCF − Capex | $29.1M | $9.6M |
| FCF MarginFCF / Revenue | 11.8% | 6.7% |
| Capex IntensityCapex / Revenue | 0.5% | 3.9% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $37.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $15.2M | ||
| Q3 25 | $44.1M | $18.6M | ||
| Q2 25 | $75.8M | $15.2M | ||
| Q1 25 | $35.0M | $4.5M | ||
| Q4 24 | $15.9M | $11.8M | ||
| Q3 24 | $12.5M | $19.0M | ||
| Q2 24 | $17.4M | $2.3M | ||
| Q1 24 | $18.3M | $13.4M |
| Q4 25 | $29.1M | $9.6M | ||
| Q3 25 | $38.0M | $14.4M | ||
| Q2 25 | $71.8M | $12.3M | ||
| Q1 25 | $32.5M | $709.0K | ||
| Q4 24 | $13.5M | $6.1M | ||
| Q3 24 | $7.7M | $12.9M | ||
| Q2 24 | $13.0M | $-204.0K | ||
| Q1 24 | $13.7M | $10.5M |
| Q4 25 | 11.8% | 6.7% | ||
| Q3 25 | 16.7% | 9.5% | ||
| Q2 25 | 34.0% | 7.9% | ||
| Q1 25 | 16.5% | 0.4% | ||
| Q4 24 | 7.1% | 4.0% | ||
| Q3 24 | 5.2% | 8.5% | ||
| Q2 24 | 9.4% | -0.1% | ||
| Q1 24 | 10.0% | 6.3% |
| Q4 25 | 0.5% | 3.9% | ||
| Q3 25 | 2.7% | 2.8% | ||
| Q2 25 | 1.9% | 1.9% | ||
| Q1 25 | 1.3% | 2.4% | ||
| Q4 24 | 1.3% | 3.7% | ||
| Q3 24 | 3.2% | 4.0% | ||
| Q2 24 | 3.2% | 1.5% | ||
| Q1 24 | 3.3% | 1.8% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 131.43× | ||
| Q1 25 | 2.23× | 6.63× | ||
| Q4 24 | — | 39.90× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.58× | ||
| Q1 24 | 1.00× | 5.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
BOOM
| Dyna Energetics Segment | $68.9M | 48% |
| Other | $57.0M | 40% |
| Nobel Clad Segment | $17.7M | 12% |
